Spero Therapeutics is developing a portfolio of novel product candidates with the potential for meaningful patient impact and significant commercial ...
Find the latest Spero Therapeutics, Inc. (SPRO) stock quote, history, news and other vital information to help you with your stock trading and investing.
Spero Therapeutics Posts Quarterly Loss Per Share Of $0.70. a month ago. Spero Therapeutics Submits New Drug Application To U.S. FDA For Tebipenem HBR For ...
Spero Therapeutics is developing novel therapies to treat highly resistant bacterial infections. The company is in partnership with Roche to develop its ...
Get the latest Spero Therapeutics Inc (SPRO) real-time quote, historical performance, charts, and other financial information to help you make more informed ...
#11.
Spero Therapeutics Inc - Company Profile and News
Spero Therapeutics, Inc. operates as a biopharmaceutical company. The Company focuses on identifying, developing, and commercializing novel treatments for ...
#12.
Spero Therapeutics - Crunchbase Company Profile & Funding
Spero Therapeutics is developing first in class therapeutics for treatment of Gram-negative infections. Cambridge, Massachusetts, United States ...
#13.
S-1 - SEC.gov
The Company was formed as Spero Therapeutics, LLC in December 2013 under the laws of the State of Delaware. On June 30, 2017, through a series of ...
SPRO | Complete Spero Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
#15.
Spero Therapeutics (@Spero_Tx) / Twitter
Spero Therapeutics. @Spero_Tx. Developing novel therapeutics for drug-resistant bacterial infections. Cambridge, MA sperotherapeutics.com Joined April 2014.
#16.
Working at Spero Therapeutics | Glassdoor
Spero Therapeutics is a global, multi-asset, clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts.
#17.
Spero Therapeutics - MassBio
Spero Therapeutics is a multi-asset clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts dedicated to developing a novel and ...
#18.
Jobs with Spero Therapeutics - BioSpace
Spero Therapeutics, Inc announced that Pfizer Inc. has made a $40 million equity investment in Spero as part of the Pfizer Breakthrough Growth Initiative, a ...
#19.
Mintz Advises Spero Therapeutics on Collaboration
Mintz advised biopharma company Spero Therapeutics on an agreement with Everest Medicines regarding the development and commercialization of a product to ...
#20.
Spero Therapeutics - REPAIR Impact Fund
Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments ...
#21.
Spero Therapeutics, Inc. - AnnualReports.com
Spero's lead product candidate, tebipenem HBr (tebipenem pivoxil hydrobromide; formerly SPR994), is being developed as the first oral carbapenem antibiotic for ...
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug ...
#23.
Spero Therapeutics, Inc. Common Stock (SPRO) - Nasdaq
Spero Therapeutics, Inc. Common Stock (SPRO) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.
#24.
Spero Therapeutics LLC - Cambridge, USA - bionity.com
Spero Therapeutics is highly committed to advancing novel treatment approaches for bacterial infections with a world-class team of biotechnology and ...
#25.
Spero Therapeutics, Inc. - SEC Report
Spero Therapeutics Inc is a US-based clinical-stage biopharmaceutical company. It focuses on identifying, developing and commercializing novel treatments for ...
Get Spero Therapeutics Inc (SPRO:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.
#27.
Spero Therapeutics Company Profile - PitchBook
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR ...
#28.
Spero Therapeutics - Innovation | Mass General Brigham
Spero Therapeutics is a product-focused biopharmaceutical company developing a pipeline of novel treatments for bacterial infections.
#29.
Spero Therapeutics | Lundbeckfonden
Spero Therapeutics. Spero has a pipeline of novel treatments for multi-drug resistant (MDR) bacterial infections. Two programs are in clinical phase I ...
#30.
Evotec and Spero Therapeutics extend collaboration to ...
Evotec and Spero Therapeutics extend collaboration to develop novel antibacterials. Hamburg, Germany - 15 December 2015: Evotec AG (Frankfurt Stock ...
#31.
Pfizer invests in Spero and licenses its antimicrobial - The ...
Massachusetts, USA-based biotech Spero Therapeutics (Nasdaq: SPRO) saw its shares close up 17.4% at $16.39 yesterday, after it announced a ...
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing novel treatments for ...
#33.
Everest Medicines Announces that Spero Therapeutics ...
Everest Medicines Announces that Spero Therapeutics Entered into Licensing Agreement with Pfizer Inc. for SPR206 in ex-U.S. and ex-Asia ...
#34.
Keyword: Spero Therapeutics - FierceBiotech
Spero Therapeutics's lead candidate will be the subject of a federal interagency collaboration to test the drug against biological threats.
#35.
Spero Therapeutics, Inc. (SPRO) Q3 2020 Earnings Call ...
Good day, and welcome to the Spero Therapeutics Third Quarter 2020 Financial Results Conference Call. Today's conference is being recorded. At ...
#37.
Shooting for PhIII, Spero tees up a new lead antibiotic in ...
Late last week Spero Therapeutics threw its S-1 into the IPO ring as the biotech ... which Spero in-licensed from Meiji Seika with a very modest upfront of ...
#38.
Company Information - Spero Therapeutics Inc - Hargreaves ...
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing novel ...
#39.
Spero Therapeutics, Inc. (SPRO) 財報分析和股票健診
Spero Therapeutics, Inc. (SPRO) 股價和財報分析，，現金股利殖利率0.0%。最關鍵的指標和圖表，幫助投資人瞭解SPRO 股票，判斷值不值得投資。
#40.
Spero Therapeutics Enters Into a Non-Dilutive Revenue ...
Spero Therapeutics Enters Into a Non-Dilutive Revenue Interest Financing Agreement With HealthCare Royalty Partners ® for Up to $125 Million.
#41.
Spero Therapeutics, LLC, United States - AMR Industry Alliance
Spero Therapeutics, LLC, United States. 675 Massachusetts Avenue 14th Floor Cambridge, MA 02139. United States. Website Twitter ...
#42.
Spero Therapeutics to advance antibiotic development via ...
Spero Therapeutics Inc. said the Biomedical Advanced Research and Development Authority has exercised its first contract option to provide ...
#44.
Biota Pharmaceuticals Sells Antibiotic Program to Spero ...
Deal will expand Spero's pipeline of candidates for bacterial infections, while reflecting Biota's focus on developing mid-stage antiviral ...
#45.
Spero Therapeutics Inc. | BioWorld
Items Tagged with 'Spero Therapeutics Inc.' ARTICLES. Anti-infective drugs speed through clinical development and regulatory approvals. Sep. 28, 2020.
#46.
Spero Therapeutics - Carb-X
Indirect Therapeutic Spero's lead program, SPR741, also called Potentiator, is a platform approach to combination therapy to treat multi-drug resistant ...
#47.
Spero Therapeutics, Inc. | SBIR.gov
Spero Therapeutics, Inc. Company Information. Address. 675 Massachusetts Ave 14th Flr. Cambridge, MA 02139-3309. United States. Information. DUNS: 080161535.
#48.
Spero Therapeutics Announces Positive Phase I Clinical Data ...
Spero Therapeutics, a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel ...
#49.
Spero Therapeutics - Tebipenem - AdisInsight
In June 2018, Spero Therapeutics presented preclinical results of tebipenem (SPR 859) against penicillin binding proteins of gram-negative bacteria at the ASM ...
#50.
Nasdaq - Spero Therapeutics, Inc. [SPRO] Virtually Rings...
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR ...
#52.
Spero Therapeutics - CB Insights
Spero Therapeutics is a global multi-asset clinical-stage biopharmaceutical company dedicated to developing a pipeline of antibacterials focused on unmet ...
#53.
Sizing Up Spero Therapeutics - Seeking Alpha
Spero Therapeutics (SPRO) is a Cambridge, Massachusetts-based clinical-stage biopharmaceutical company that IPO'd in 2017.
#54.
tebipenem hydrobromide - Drugs.com
Spero Therapeutics Submits New Drug Application to U.S. FDA for Tebipenem HBr for the Treatment of Complicated Urinary Tract Infections ...
#55.
Spero Therapeutics raises $30M to support its drug delivery ...
Cambridge, MA's Spero Therapeutics has raised $30 million in Series B financing to develop its so-called Potentiator Platform to improve ...
#56.
Spero Therapeutics to Present at Upcoming Investor ... - KULR-8
CAMBRIDGE, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical ...
#57.
Spero Therapeutics - Wiki | Golden
Spero's lead product candidate is SPR994, which is designed to be the first oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative ...
#58.
Spero Therapeutics (SPRO) - Forbes
Spero Therapeutics (SPRO). $14.41. -0.70 (-4.63%). As of November 29 4:00:00 PM EST. License Error: Access from crawling bot. Q-Factor Score.
#59.
Spero Therapeutics Announces Fourth Quarter and Full Year ...
Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and ...
#60.
Google's Venture Arm Leads $51.7M Investment in ... - Xconomy
Despite the growing problem of drug-resistant bacteria, few new antibiotics have been developed in recent decades. Spero Therapeutics is ...
#61.
Spero Therapeutics Announces Collaboration with GMRI to ...
SPR720 was discovered by Vertex Pharmaceuticals and was acquired by Spero Therapeutics in 2016. Vertex and Spero have reached an agreement to ...
#62.
Spero Therapeutics Announces Positive Topline Results From ...
Spero Therapeutics, Inc. recently announced positive topline results from ADAPT-PO, the pivotal Phase 3 clinical trial evaluating Spero's oral antibiotic.
Spero Therapeutics Inc (US:SPRO) has 222 institutional owners and shareholders (aka shareholding pattern) that have filed 13D/G or 13F forms with the ...
#68.
Semiconductor Equipment | Benzinga
HC Wainwright & Co. raised the price target on Spero Therapeutics Inc (NASDAQ: SPRO) from $28 to $33. Spero Therapeutics shares rose 2.8% to close at $15.
#69.
ceo message to employees march 2021 - Utrade.com.gh ...
By Ankit Mahadevia, CEO and founder of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC.
#71.
Ellington and associates raleigh - Fotografía Wonderland Chile
Ankit is co-founder, president, and chief executive officer of Spero Therapeutics. Residents at 608 Marlowe Rd, Raleigh NC: Debbie S Cooper (919) 781-8892, ...
#72.
Optimizing The Treatment Of Complicated UTIs AUAUniversity ...
... ACKNOWLEDGEMENT: This activity is supported by an independent educational grant from Spero Therapeutics. 202 episodes.
#73.
Sarepta Therapeutics Announces Inducement Grants Under ...
#75.
Handbook of Preformulation: Chemical, Biological, and ...
... Tetraphase Pharmaceuticals, Macrolide Pharmaceuticals, Iterum Therapeutics, Spero Therapeutics, and Entasis Therapeutics. 1.1.4 Artificial Intelligence ...
#76.
Comprehensive Medicinal Chemistry III - 第 x 頁 - Google 圖書結果
... Lisbon, Portugal K L Powell ReViral Ltd, Stevenage Bioscience Catalyst, Stevenage, United Kingdom M J Pucci Spero Therapeutics, Cambridge, MA, ...
#77.
Antibacterials: Volume II - 第 202 頁 - Google 圖書結果
... combination with the clinically used antibiotic ciprofloxacin in sub-therapeutic doses. ... further developed in collaboration with Spero Therapeutics.
Jonathan Spero, M.D. is an expert on medical risk management in the meeting industry, healthcare cost containment in the employer space, and a leader in the ...
#80.
Sarepta Therapeutics | Biopharmaceutical Company for Rare ...
We are focused on the development of precision genetic medicines to treat rare neuromuscular and central nervous system diseases. Learn more about Sarepta.
#81.
Spero CBD | StartEngine
In addition to owning a stake in Spero's success all of our crowd funding investors will receive lifetime discounts on all of Spero CBD products. This is a ...
#82.
Sutro Biopharma, Inc. is a public biotechnology company ...
It focuses to design therapeutics using potent modalities, including cytokine based immune-oncology (I/O) therapeutics, antibody-drug conjugates (ADCs) and ...
#83.
Spero Rehab Topic and Bio - Team Luke – Hope For Minds
Spero Rehabs Fundamental Focus on Recovery to Foster True Functional Independence: Spero Rehab is a cutting edge outpatient neurological setting that treats ...
#84.
Phico Therapeutics awarded up to $18.2 million USD - News ...
Phico Therapeutics awarded up to $18.2 million USD (c.£13.2 million GBP) CARB-X funding to advance SASPject antibacterial therapy through Phase ...
#86.
If Billy Sunday Comes to Town - Delusion as a Religious ...
Spero sketches a convincing twofold picture of an archaic Job with a layered ... In psychiatric practice writing an autobiography is used as a therapeutic ...
#87.
AIDS Bibliography, 1986-1987: 2697 Citations
... Rinaldo CR ; Kingsley LA ; Steffensen DO ; Bowman R ; Spero JA ; Lewis JH . ... Viral -- * ANALYSIS / Factor IX* THERAPEUTIC USE / Factor VIII ...
#88.
Index-catalogue of the Library of the Surgeon-General's ...
Suggestive therapeutics . 80 . The same . ... spero Alpino de præsagienda vita et morte 12. Venetiis , 1574 , 186-229 . ægrotantium .
spero therapeutics 在 Nasdaq Spotlight: Spero Therapeutics - YouTube 的推薦與評價
... <看更多>